Literature DB >> 30835683

Results of more than 20 years of follow-up in pediatric patients with moyamoya disease undergoing pial synangiosis.

Coleman P Riordan, Armide Storey, David J Cote, Edward R Smith, R Michael Scott.   

Abstract

OBJECTIVEThere are limited data on the long-term outcomes for children undergoing surgical revascularization for moyamoya disease (MMD) in North America. The authors present a series of pediatric MMD patients who underwent a standard revascularization procedure, pial synangiosis, more than 20 years previously at a single institution by a single surgical team.METHODSThis study is a retrospective review of all patients aged 21 years or younger treated for MMD at Boston Children's Hospital who were operated on more than 20 years previously by the senior author (R.M.S.). Radiographic and operative reports, outpatient clinical records, and communications with patients and families were reviewed to document current clinical status, ability to perform daily activities, and concurrent or new medical conditions.RESULTSA total of 59 patients (38 female [64.4%], 21 male [35.6%]; median age at surgery 6.2 years [IQR 0.5-21 years]) were identified who were diagnosed with MMD and underwent surgical revascularization procedures more than 20 years previously. Clinically, all but 2 patients (96.6%) presented with the following symptoms alone or in combination: 43 (73%) presented with stroke, 22 (37%) with transient ischemic attack, 12 (20%) with seizures, 7 (12%) with headache, 3 (5%) with choreiform movements, and 2 (3%) with hemorrhage; MMD was incidentally detected in 2 patients (3%). Five patients had unilateral MMD at presentation, but 3 of these ultimately progressed to develop bilateral MMD after an average of 16 months; therefore, pial synangiosis was ultimately performed in a total of 116 hemispheres during the study period. Clinical follow-up was available at a median interval of 20.6 years (IQR 16.1-23.2 years). Modified Rankin Scale scores were stable or improved in 43 of 50 patients with evaluable data; 45 of 55 are currently independent. There were 6 patient deaths (10.2%; 3 due to intracranial hemorrhage, 2 due to tumor-related complications, and 1 due to pulmonary artery stenosis), 4 of whom had a history of previous cranial radiation. One patient (1.7%) experienced a late stroke. Synangiosis vessels remained patent on all available late MRI and MRA studies. Four patients reported uneventful pregnancies and vaginal deliveries years following their revascularization procedures.CONCLUSIONSRevascularization for MMD by pial synangiosis appears to confer protection from stroke for pediatric patients over long-term follow-up. A history of cranial radiation was present in 4 of the 5 patients who died and in the lone patient with late stroke. Most patients can expect productive, independent lives following revascularization surgery in the absence of significant preoperative neurological deficits and comorbidities.

Entities:  

Keywords:  EDAS = encephaloduroarteriosynangiosis; MMD = moyamoya disease; NF1 = neurofibromatosis type 1; TIA = transient ischemic attack; cerebrovascular; mRS = modified Rankin Scale; moyamoya; outcomes; pediatric; revascularization; stroke; vascular disorders

Year:  2019        PMID: 30835683     DOI: 10.3171/2019.1.PEDS18457

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  4 in total

Review 1.  Idiopathic Non-atherosclerotic Carotid Artery Disease.

Authors:  Andrea Harriott
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-11-14

2.  Seizure outcome in moyamoya after indirect revascularization in pediatric patients: Retrospective study and literature review.

Authors:  Abdullah Alramadan; Anwar Ul Haq; Sarah Basindwah; Essam Alshail
Journal:  Surg Neurol Int       Date:  2021-02-23

Review 3.  Pathophysiology of Vascular Stenosis and Remodeling in Moyamoya Disease.

Authors:  Brandon M Fox; Kirsten B Dorschel; Michael T Lawton; John E Wanebo
Journal:  Front Neurol       Date:  2021-09-03       Impact factor: 4.003

Review 4.  [Advances in surgical treatment of ischemic cerebrovascular disease].

Authors:  Jianmin Zhang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2019-05-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.